BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 18214043)

  • 1. Immunohistochemical expression of MRP2 and clinical resistance to platinum-based chemotherapy in small cell lung cancer.
    Ushijima R; Takayama K; Izumi M; Harada T; Horiuchi Y; Uchino J; Hara N; Nakanishi Y
    Anticancer Res; 2007; 27(6C):4351-8. PubMed ID: 18214043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Expression and prognostic value of the drug resistance markers P-gp, Mrp1, Mrp2, and Lrp in ovarian carcinoma].
    Katsaros D; Fracchioli S; Arts HJ; de Vries EG; Danese S; Richiardi G; Arisio R; Gordini G; Van der Zee AG; Suurmeijer AJ; Massobrio M
    Minerva Ginecol; 1999 Dec; 51(12):463-70. PubMed ID: 10767994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program.
    Filipits M; Haddad V; Schmid K; Huynh A; Dunant A; André F; Brambilla E; Stahel R; Pignon JP; Soria JC; Popper HH; Le Chevalier T; Pirker R
    Clin Cancer Res; 2007 Jul; 13(13):3892-8. PubMed ID: 17606722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels.
    Young LC; Campling BG; Cole SP; Deeley RG; Gerlach JH
    Clin Cancer Res; 2001 Jun; 7(6):1798-804. PubMed ID: 11410522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multidrug resistance in small cell lung cancer: expression of P-glycoprotein, multidrug resistance protein 1 and lung resistance protein in chemo-naive patients and in relapsed disease.
    Triller N; Korosec P; Kern I; Kosnik M; Debeljak A
    Lung Cancer; 2006 Nov; 54(2):235-40. PubMed ID: 16934363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer.
    Kim YH; Ishii G; Goto K; Ota S; Kubota K; Murata Y; Mishima M; Saijo N; Nishiwaki Y; Ochiai A
    Lung Cancer; 2009 Jul; 65(1):105-11. PubMed ID: 19036469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma.
    Arts HJ; Katsaros D; de Vries EG; Massobrio M; Genta F; Danese S; Arisio R; Scheper RJ; Kool M; Scheffer GL; Willemse PH; van der Zee AG; Suurmeijer AJ
    Clin Cancer Res; 1999 Oct; 5(10):2798-805. PubMed ID: 10537344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Expression of proteins associated with multidrug resistance and resistance to chemotherapy in lung cancer].
    Paredes Lario A; Blanco García C; Echenique Elizondo M; Lobo C
    Arch Bronconeumol; 2007 Sep; 43(9):479-84. PubMed ID: 17919413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA expression of MDR1/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response.
    Materna V; Pleger J; Hoffmann U; Lage H
    Gynecol Oncol; 2004 Jul; 94(1):152-60. PubMed ID: 15262134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of chemotherapy response with P-glycoprotein, multidrug resistance-related protein-1, and lung resistance-related protein expression in untreated small cell lung cancer.
    Yeh JJ; Hsu NY; Hsu WH; Tsai CH; Lin CC; Liang JA
    Lung; 2005; 183(3):177-83. PubMed ID: 16078039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiation of the P-gp and MRP1 multidrug resistance systems by mobile lipid 1H-NMR spectroscopy and phosphatidylserine externalization.
    Mannechez A; Collet B; Payen L; Lecureur V; Fardel O; Le Moyec L; de Certaines JD; Leray G
    Anticancer Res; 2001; 21(6A):3915-9. PubMed ID: 11911269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between chemotherapy response of small cell lung cancer and P-glycoprotein or multidrug resistance-related protein expression.
    Hsia TC; Lin CC; Wang JJ; Ho ST; Kao A
    Lung; 2002; 180(3):173-9. PubMed ID: 12177731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. To predict response chemotherapy using technetium-99m tetrofosmin chest images in patients with untreated small cell lung cancer and compare with p-glycoprotein, multidrug resistance related protein-1, and lung resistance-related protein expression.
    Kuo TH; Liu FY; Chuang CY; Wu HS; Wang JJ; Kao A
    Nucl Med Biol; 2003 Aug; 30(6):627-32. PubMed ID: 12900288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma.
    Guminski AD; Balleine RL; Chiew YE; Webster LR; Tapner M; Farrell GC; Harnett PR; Defazio A
    Gynecol Oncol; 2006 Feb; 100(2):239-46. PubMed ID: 16213010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fractionated irradiation of H69 small-cell lung cancer cells causes stable radiation and drug resistance with increased MRP1, MRP2, and topoisomerase IIalpha expression.
    Henness S; Davey MW; Harvie RM; Davey RA
    Int J Radiat Oncol Biol Phys; 2002 Nov; 54(3):895-902. PubMed ID: 12377343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans.
    Oswald S; Haenisch S; Fricke C; Sudhop T; Remmler C; Giessmann T; Jedlitschky G; Adam U; Dazert E; Warzok R; Wacke W; Cascorbi I; Kroemer HK; Weitschies W; von Bergmann K; Siegmund W
    Clin Pharmacol Ther; 2006 Mar; 79(3):206-17. PubMed ID: 16513445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer.
    Yoh K; Ishii G; Yokose T; Minegishi Y; Tsuta K; Goto K; Nishiwaki Y; Kodama T; Suga M; Ochiai A
    Clin Cancer Res; 2004 Mar; 10(5):1691-7. PubMed ID: 15014021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma.
    Ohishi Y; Oda Y; Uchiumi T; Kobayashi H; Hirakawa T; Miyamoto S; Kinukawa N; Nakano H; Kuwano M; Tsuneyoshi M
    Clin Cancer Res; 2002 Dec; 8(12):3767-75. PubMed ID: 12473588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. To predict chemotherapy response using technetium-99m tetrofosmin and compare with p-glycoprotein and multidrug resistance related protein-1 expression in patients with untreated small cell lung cancer.
    Shiau YC; Tsai SC; Wang JJ; Ho YJ; Ho ST; Kao CH
    Cancer Lett; 2001 Aug; 169(2):181-8. PubMed ID: 11431107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas.
    Yakirevich E; Sabo E; Naroditsky I; Sova Y; Lavie O; Resnick MB
    Gynecol Oncol; 2006 Jan; 100(1):152-9. PubMed ID: 16198399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.